Files in this item



application/pdfNGUYEN-DISSERTATION-2016.pdf (7MB)Restricted to U of Illinois
(no description provided)PDF


Title:Design, synthesis, and biological activities of small molecules that target myotonic dystrophy
Author(s):Nguyen, Lien Thi Thuy
Director of Research:Zimmerman, Steven C
Doctoral Committee Chair(s):Zimmerman, Steven C
Doctoral Committee Member(s):Hergenrother, Paul J; Katzenellenbogen , John A; Oldfield, Eric
Department / Program:Chemistry
Degree Granting Institution:University of Illinois at Urbana-Champaign
Subject(s):Myotonic Dystrophy
Drug development
Abstract:Myotonic dystrophy (DM) is a triple-repeat expansion, multi-systemic disease that affects one in eight thousand people worldwide. The cause of the disease is a progressive, abnormal expansion of CTG repeats (CUGexp) in the 3'-UTR of the DMPK gene (DM1) and CCTG repeats (CCUGexp) in the intron 1 of the ZNP9 gene (DM2). The sequestration of muscleblind-like proteins (MBNL) by CUGexp or CCUGexp causes splicing defects in more than 100 pre-mRNAs, resulting in various disease phenotypes. As such, therapeutic development for DM has mainly focused on agents targeting the CUGexp/CCUGexp -MBNL1 interaction. This dissertation focuses on the development of rationally designed small molecules that target CUGexp and CCUGexp, including their synthesis and studies of their biological activity. The background of DM with a focus on its molecular mechanism and various therapeutic approaches are reviewed in Chapter 1. Chapter 2 includes the story of how simple ligands targeting CUGexp have been developed and investigations of the biological activity of acridine-based and bisamidinium-based ligands synthesized by others in our group. Chapter 3 focuses on the design, synthesis, and biological activity of bisamidinium-based ligands that target CCUGexp. Because other toxic pathways, including microRNA dysregulation in DM1 heart tissue and the production of polypeptides via repeat-associated non-ATG translation, are induced by CUGexp, recent efforts on DM1 therapeutic approaches have moved beyond just preventing the formation of CUGexp-MBNL1 complex and further focused on regulating the level of toxic CUGexp. Thus, Chapter 4 discusses a multi-target approach for DM1 in which a ligand with a RNA-cleaving unit can bind both CTGexp and CUGexp and regulate the level of CUGexp.
Issue Date:2016-04-01
Rights Information:Copyright 2016 Lien Nguyen
Date Available in IDEALS:2016-07-07
Date Deposited:2016-05

This item appears in the following Collection(s)

Item Statistics